Stockreport

AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer

AnaptysBio, Inc.  (ANAB) 
Last anaptysbio, inc. earnings: 3/2 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: ir.anaptysbio.com/investor-relations
PDF Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or r [Read more]